CSIMarket Company Name, Ticker, Suppliers, else..
 
Viatris Inc   (NASDAQ: VTRS)
 
Price: $19.9100 $0.94 4.955%
Day's High: $19.940000534057617 Week Perf: 6.64 %
Day's Low: $ 18.80 30 Day Perf: 14.16 %
Volume (M): 14,435,340 52 Wk High: $ 19.96
Volume (M$): $ 0 52 Wk Avg: $15.17
Open: $18.79 52 Wk Low: $9.99



 Market Capitalization (Millions $) 22,869
 Shares Outstanding (Millions) 1,149
 Employees 30,000
 Revenues (TTM) (Millions $) 14,727
 Net Income (TTM) (Millions $) -608
 Cash Flow (TTM) (Millions $) 802
 Capital Exp. (TTM) (Millions $) 375

Business Description


Viatris Inc. is a global pharmaceutical company focused on providing affordable access to high-quality medicines for patients worldwide. The company was formed as a result of the merger between Mylan N.V. and Pfizeres Upjohn business in November 2020. Headquartered in Pittsburgh, Pennsylvania, Viatris has operations in more than 165 countries, and its medicines are used by more than one billion people globally.

The company has a diverse portfolio of products that span across various therapeutic areas such as cardiovascular, central nervous system, dermatology, gastroenterology, HIV/AIDS, and oncology. Some of its well-known brands include Lipitor, Advil, Celebrex, and Viagra.

Viatris employs more than 45,000 people worldwide and has a strong commitment to sustainability and corporate social responsibility. The company strives to reduce its environmental footprint by promoting responsible manufacturing practices, sourcing renewable energy, and reducing water usage.

In terms of financials, Viatris had revenues of $11.9 billion in 2020, and its products are sold in more than 165 countries worldwide. The company's market capitalization as of August 2021 is approximately $15 billion.

Viatris leadership is committed to driving growth and innovation by investing in its portfolio, technology, and partnerships with other companies. The company's leadership team is composed of experienced executives with extensive experience in the pharmaceutical industry, including Heather Bresch, CEO, and Rajiv Malik, President.

Overall, Viatris is a global pharmaceutical company focused on delivering high-quality medicines at affordable prices to patients worldwide. The company's diverse portfolio of products, global reach, commitment to sustainability, and strong leadership all contribute to its success and continued growth.


   Company Address: 1000 Mylan Boulevard Canonsburg 15317 PA
   Company Phone Number: 514-1800   Stock Exchange / Ticker: NASDAQ VTRS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.21%    
BMY   -0.54%    
JNJ        1.11% 
LLY   -4.48%    
MRK   -1.87%    
PFE   -3.7%    
• View Complete Report
   



Announcement

Justice Awaits Viatris Investors Unite for Class Action Lawsuit,

Published Mon, Jun 2 2025 8:38 PM UTC

The Law of the Land: Viatris Inc. Investors Urged to Stand Up for JusticeIn a striking turn of events, investors of Viatris Inc. (NASDAQ: VTRS) are being called to action as Bronstein, Gewirtz & Grossman LLC, a renowned law firm, initiates a class action lawsuit against the pharmaceutical company and its officers. This announcement on June 2, 2025, beckons those who have su...
Announcement

Legal Actions on the Rise Viatris Inc. Faces Class Action Lawsuit Amid Investor Concerns

Published Sun, May 11 2025 5:19 AM UTC

This article reviews the recent developments concerning Viatris Inc. (NASDAQ: VTRS), which is currently facing a class action lawsuit filed by a prominent law firm, Bronstein, Gewirtz & Grossman LLC. This legal action has arisen amid allegations that certain officers of the company may have misled investors, leading to substantial financial losses. The implications of this l...
Announcement

Investors Urged to Seek Counsel Ahead of Deadline in Viatris Inc. Securities Class Action

Published Mon, May 5 2025 6:06 AM UTC

By July 4, 2025 - New York Rosen Law Firm, a prominent global investor rights law firm, is encouraging investors of Viatris Inc. (NASDAQ: VTRS) to secure legal representation before the looming lead plaintiff deadline in a securities class action. This reminder is particularly pertinent for those who purchased Viatris securities between August 8, 2024, and February 26, 2025...
Announcement

Viatris Investors at a Crossroads Navigating Class Action Lawsuits and Insider Activity

Published Fri, May 2 2025 6:57 PM UTC

In the rapidly evolving landscape of pharmaceutical stocks, Viatris Inc. (NASDAQ: VTRS) has become a focal point for investors following the announcement of a class action securities lawsuit. Investors have until June 3, 2025, to join the legal effort spearheaded by Levi & Korsinsky, LLP, alleging securities fraud against the company. This development has sparked a keen inte...
Announcement

Navigating Financial Straits Viatris Inc.s Improving Receivables Amidst Sector Challenges,

Published Tue, Apr 29 2025 9:25 AM UTC

Navigating Financial Straits: Viatris Inc. s Improving Receivables Amidst Sector Challenges In the fast-evolving landscape of pharmaceutical sciences, fiscal resilience stands as a paramount pillar for sustained success. Viatris Inc. (NASDAQ: VTRS), a notable player in this realm, has recently been spotlighted with significant financial developments that warrant attention fr...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.55
Price to Sales (Expected) -
Price to Book 1.67
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.28
Working Capital Ratio 1.55
Leverage Ratio (MRQ) 1.53
Total Debt to Equity 0.97
Interest Coverage (TTM) 7.74
Debt Coverage (TTM) 0.26

Per Share Current
Earnings (TTM) -0.52 $
Revenues (TTM) 12.82 $
Cash Flow (TTM) 0.7 $
Cash 1.62 $
Book Value 11.91 $
Dividend (TTM) 0.48 $

Efficiency Current
Revenue per Employee (TTM) 490,897
Net Income per Employee (TTM) -20,260
Receivable Turnover Ratio (TTM) 5.2
Inventory Turnover Ratio (TTM) 2.43
Asset Turnover Ratio (TTM) 0.4

Profitability Ratios Current
Gross Margin (MRQ) 38.35 %
Operating Margin (MRQ) 6.97 %
Net Margin (MRQ) -8.68 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield 2.41 %
Pay out Ratio (TTM) -



Viatris Inc's Segments
Brands    192.35 % of total Revenue
Generics    100.76 % of total Revenue
Lipitor ®    36.43 % of total Revenue
Norvasc ®    16.01 % of total Revenue
EpiPen® Auto-Injectors    10.3 % of total Revenue
Lyrica ®    9.48 % of total Revenue
Creon ®    7.81 % of total Revenue
Viagra ®    8.05 % of total Revenue
Zoloft ®    5.94 % of total Revenue
Celebrex ®    5.7 % of total Revenue
Effexor ®    5.14 % of total Revenue
Xalabrands    3.25 % of total Revenue
Influvac ®    2.68 % of total Revenue
Yupelri ®    5.46 % of total Revenue
Xanax ®    2.92 % of total Revenue
Amitiza ®    2.93 % of total Revenue
Dymista ®    3 % of total Revenue
Product and Service, Other    0.15 % of total Revenue
Developed Markets    172.12 % of total Revenue
Greater China    55.91 % of total Revenue
Japan, Australia and New Zealand    22.96 % of total Revenue
Emerging Markets    43 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.